Smart-Air 4mg Recalcine Treatment Treatment for chronic bronchial asthma (1 blister x 10 tablets)

Dosage form Box of 1 blister x 10 tablets
Specifications Montelukast

Ingredient

Composition information	Content
Montelukast	4mg

Uses

Indications

Smart-Air drugs are indicated in the following cases:

Preventive and treat chronic bronchial asthma in adults and children greater than 2 years old. Cysteinyl - Leukotrience CYSLT1. Cysteinyl - Leukotrienes (LTC4, LTD4, LTE4) is the result of arachidonic acid metabolism released from several types of cells such as moisturizers and EOSIN -preferred cells, they combined with cysteinyl receptor - Leukotrience on the air pathway.

A combination of cysteinyl - Leukotrience with receptors related to asthma pathology, including edema in the airway, smooth muscle contraction and replacing the active cells of the anti -inflammatory process, these factors cause symptoms of asthma.

pharmacokinetic

Montelukast absorbs quickly through oral and placed under the tongue, the peak concentration in the serum reaches 3-4 hours after taking the medication, and 2 - 2.5 hours after placing under the tongue. The maximum bioavailability and maximum serum levels are not affected by food in the digestive tract, in case of under the tongue can increase bioavailability when the stomach is empty.

Before taking Smart-Air 4mg Recalcine Treatment Treatment for chronic bronchial asthma (1 blister x 10 tablets)

How to use

The drug is taken once a day. Prophylaxis and treatment of asthma should take medicine in the evening. Treatment of allergic rhinitis, drug use time depending on the needs of each object.

For patients with both asthma and allergic rhinitis, they should be used a dose every day, in the evening.

Dosage

Adults and children> 15 years old

1 tablet daily 10 mg.

Children from 6 - 14 years old

1 tablet 5 mg.

Children from 2 - 6 years old

DAY 1 TIEN 4 mg.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? The most common reactions include abdominal pain, drowsiness, thirst, headache, vomiting and agitation. There is no Montelukast research that can be separated through the peritoneal or dialysis.

What to do when forgetting a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Do not drink twice as prescribed.

Side Effects

When using Smart-Air, you may experience unwanted effects (ADR).

Common, ADR> 1/100:

Neurology: headache.

Uncommon, 1/1000

Liver: Increased liver enzyme.

digestive: abdominal pain or stomach, indigestion, gastrointestinal infections. nerve: weakness, fatigue.

Respiratory: cough, nasal congestion.

Other: toothache, sickness, fever, skin change.

Rare, 1/10000

urinary tract: pus.

Unknown frequency ADR:

Hematology: Reducing peripheral Eosin cells in asthma patients, Eosin -like systems of the whole system, manifesting vasculitis with Churg - Strauss syndrome.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Smart-Air drugs contraindicated in the following cases:

Patients with a history of hypersensitivity to Montelukast or one of the ingredients of the drug.

Caution when using

Safe and effective use of drugs for children under 2 years of age has not been set up, do not use drugs for these objects.

Use medication for patients with moderate to medium to medium to medium -sized patients as well as patients with clinical manifestations of chronic liver disease, which must be assessed by Montelukast's exhaust time that may increase (on average 7.4 hours). However, in some cases, the dose is no need to adjust. Do not use Montelukast for patients with severe liver failure.

Patients should be recommended never to use oral Montelukast to treat acute asthma attacks and always have appropriate emergency medicine. If the acute attack occurs, it is recommended to use the inhaled beta -shaped shipping drug. Patients should ask the doctor's advice as soon as possible if they need to inhale more beta -shorter -acting drug owner than usual.

Do not suddenly replace Montelukast with inhaled or drinking corticosteroids. No data proves that oral corticosteroids can reduce the dose when using Montelukast simultaneously.

Mental events have been reported in adults, adolescents and children using Montelukast. Patients and physicians should be alert to mental events. The prescription should carefully evaluate the risks and benefits of continuing treatment with Montelukast if the above events occur.

The ability to drive and operate machinery

The drug can cause drowsiness, do not use drugs for drivers or machinery.

Pregnancy

There is no sufficient research on human use, so it is necessary to consider the benefits and risks for the fetus before using Montelukast.

Breastfeeding period

Unknown excretion of Montelukast through breast milk. Be cautious when using the drug for this object.

Drug interaction

Montelukast has been used with other common drugs in prevention and treatment of asthma for a long time without side effects. In addition, the drug has been used in combination with benzodiazepine, anti -stuffy drugs, nonsteroidal anti -inflammatory drugs, sleeping pills - sedatives and thyroid hormones without increasing side effects.

In studies on drug interactions with normal doses, Montelukast does not significantly affect the pharmacokinetics of theophyllline, Warfarin, Terfenadine, Digoxin, oral contraceptives, Prednisone, Prednisolon.

Montelukast is metabolized by Cytochrom P450 3A4 and 2C9, induction or inhibitors of this enzyme system (such as erythromycin, ketoconazol, or fluconaol) may affect Montelukast serum concentration.

Phenobarbital is a strong Cytochrom P450 induction, when used simultaneously reduces the area under the curve of Montelukast 40%, so patients use these strong enzyme induction drugs to re -evaluate clinical response and / or wise effects.

Storage

A cool dry place, below 30 degrees Celsius, avoiding light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.